Facebook Instagram Pinterest Reddit Tumblr X Youtube

Home
About
News
Events
Shop
Directory
Contact Us

Search

Sign in

Welcome! Log into your account

your username

your password

Forgot your password? Get help

Password recovery

Recover your password

your email

A password will be e-mailed to you.

Home
About
News
Events
Shop
Directory
Contact Us

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

By

-

July 21, 2026

3

Post Content

Previous articleThe Vital Conference: Breckenridge 2026

Next articlePα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

RELATED ARTICLES MORE FROM AUTHOR

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

Newsletter

EDITOR PICKS

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

FOLLOW US

Facebook Instagram Pinterest Reddit Tumblr X Youtube

©

MORE STORIES

Psychedelic Philanthropy Is Entering Its Next Phase